Venrock Adviser, LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Venrock Adviser, LLC reported 33 stock positions worth $3.3 billion. Its top holding was Apogee Therapeutics (APGE) at 34.2% of the portfolio, followed by Oruka Therapeutics (ORKA, 12.0%) and Erasca (ERAS, 9.9%). Compared with Q1 2026, it opened 4 new positions, sold out of 4, added to 5 and reduced 5. The biggest buy was a new position in Achieve Life Sciences (ACHV) and the biggest sale an exit from Kalvista Pharmaceuticals (KALV).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001615982
- Portfolio Value
- $3.3B (Q2 2026)
- SEC Filing
- 0001615982-26-000015 ↗ filed Aug 14, 2026
Holdings Value
Holdings 33 stocks · $3.3B
| APGE Apogee Therapeutics Inc. | 34.18% | 8,493,321 | $1.1B | No change |
| ORKA Oruka Therapeutics Inc. | 11.97% | 4,148,428 | $394.8M | No change |
| ERAS Erasca Inc. | 9.94% | 17,891,812 | $327.8M | Add +9.2% |
| SYRE Spyre Therapeutics Inc. | 8.04% | 2,985,448 | $265.0M | Reduce -19.0% |
| DNTH Dianthus Therapeutics Inc. | 3.49% | 1,180,000 | $115.0M | No change |
| OCUL Ocular Therapeutix Inc. | 3.08% | 10,346,926 | $101.6M | No change |
| DMRA Damora Therapeutics Inc. | 2.84% | 3,603,595 | $93.7M | No change |
| SVRA Savara Inc. | 2.75% | 14,745,943 | $90.8M | Add +7.3% |
| JBIO Jade Biosciences Inc. | 2.17% | 3,220,364 | $71.6M | No change |
| COGT Cogent Biosciences Inc. | 1.93% | 1,642,166 | $63.6M | Reduce -17.9% |
| VRDN Viridian Therapeutics Inc. | 1.81% | 3,257,917 | $59.8M | Reduce -16.1% |
| VOR Vor Biopharma Inc. | 1.70% | 3,041,719 | $56.0M | No change |
| DYN Dyne Therapeutics Inc. | 1.46% | 2,173,913 | $48.3M | No change |
| MAZE Maze Therapeutics Inc. | 1.45% | 1,602,034 | $47.8M | No change |
| RLMD Relmada Therapeutics Inc. | 1.44% | 6,844,305 | $47.4M | Add +41.3% |
| ORIC Oric Pharmaceuticals Inc. | 1.42% | 4,319,765 | $46.8M | No change |
| CBIO Crescent Biopharma Inc. | 1.16% | 2,133,576 | $38.4M | No change |
| ZURA Zura Bio Ltd. | 1.15% | 6,434,990 | $38.0M | No change |
| ANL Adlai Nortye Group Ltd. | 1.12% | 3,212,731 | $36.9M | No change |
| ELVN Enliven Therapeutics Inc. | 0.81% | 526,331 | $26.7M | Reduce -69.5% |
| HELP Cybin Inc. | 0.77% | 3,851,654 | $25.5M | No change |
| CGEM Cullinan Therapeutics Inc. | 0.76% | 1,379,965 | $25.1M | No change |
| IPSC Century Therapeutics Inc. | 0.65% | 8,695,652 | $21.3M | No change |
| ARTV Artiva Biotherapeutics Inc. | 0.60% | 2,043,596 | $19.8M | Add +27.0% |
| CTMX Cytomx Therapeutics Inc. | 0.57% | 4,982,124 | $18.7M | Reduce -50.1% |
| ACHV Achieve Life Sciences Inc. | 0.54% | 2,751,032 | $18.0M | New |
| PBLS Parabilis Medicines Inc. | 0.52% | 625,000 | $17.1M | New |
| SRZN Surrozen Inc. | 0.50% | 632,931 | $16.4M | No change |
| KRRO Korro Bio Inc. | 0.40% | 1,009,500 | $13.3M | No change |
| ANRO Alto Neuroscience Inc. | 0.40% | 500,000 | $13.2M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.27% | 1,934,253 | $9.0M | Add +485.2% |
| RACC Research Alliance Corp. Class A | 0.10% | 300,000 | $3.2M | New |
| INM Inmed Pharmaceuticals Inc. | 0.00% | 32,685 | $51K | New |
Portfolio Sells Q1 2026 → Q2 2026
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −4.86 |
| ELVN Enliven Therapeutics Inc. | Reduce -69.5% | 0.81% | −1.72 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −1.21 |
| CTMX Cytomx Therapeutics Inc. | Reduce -50.1% | 0.57% | −1.18 |
| VRDN Viridian Therapeutics Inc. | Reduce -16.1% | 1.81% | −1.02 |
| TENX Tenax Therapeutics Inc. | Sold out | 0.00% | −1.00 |
| COGT Cogent Biosciences Inc. | Reduce -17.9% | 1.93% | −0.95 |
| SEPN Septerna Inc. | Sold out | 0.00% | −0.45 |
| SYRE Spyre Therapeutics Inc. | Reduce -19.0% | 8.04% | +1.10 |
Portfolio Buys Q1 2026 → Q2 2026
| ACHV Achieve Life Sciences Inc. | New | 0.54% | +0.54 |
| PBLS Parabilis Medicines Inc. | New | 0.52% | +0.52 |
| XFOR X4 Pharmaceuticals Inc. | Add +485.2% | 0.27% | +0.22 |
| ARTV Artiva Biotherapeutics Inc. | Add +27.0% | 0.60% | +0.21 |
| RLMD Relmada Therapeutics Inc. | Add +41.3% | 1.44% | +0.18 |
| RACC Research Alliance Corp. Class A | New | 0.10% | +0.10 |
| ERAS Erasca Inc. | Add +9.2% | 9.94% | +0.04 |
| INM Inmed Pharmaceuticals Inc. | New | 0.00% | +0.00 |
| SVRA Savara Inc. | Add +7.3% | 2.75% | −0.05 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $3.3B | APGE, ORKA, ERAS, SYRE, DNTH |
| Q1 2026 | 33 | $2.7B | APGE, ERAS, ORKA, SYRE, KALV |
| Q4 2025 | 27 | $2.0B | APGE, ORKA, VRDN, SYRE, KALV |
| Q3 2025 | 33 | $1.8B | APGE, MTSR, OCUL, CDTX, VRDN |
| Q2 2025 | 31 | $1.3B | APGE, OCUL, MTSR, ELVN, KALV |
| Q1 2025 | 37 | $1.2B | APGE, MTSR, OCUL, ELVN, KALV |
| Q4 2024 | 37 | $1.5B | APGE, OCUL, ELVN, PRAX, VRDN |
| Q3 2024 | 38 | $1.9B | APGE, OCUL, ELVN, VRDN, APLT |
| Q2 2024 | 35 | $1.6B | APGE, ELVN, FDMT, OCUL, DYN |
| Q1 2024 | 38 | $2.1B | APGE, FDMT, OCUL, SYRE, MRUS |